MXPA05008137A - Antagonistas y agonistas de 5ht7. - Google Patents

Antagonistas y agonistas de 5ht7.

Info

Publication number
MXPA05008137A
MXPA05008137A MXPA05008137A MXPA05008137A MXPA05008137A MX PA05008137 A MXPA05008137 A MX PA05008137A MX PA05008137 A MXPA05008137 A MX PA05008137A MX PA05008137 A MXPA05008137 A MX PA05008137A MX PA05008137 A MXPA05008137 A MX PA05008137A
Authority
MX
Mexico
Prior art keywords
user
questions
fsd
sexual function
assessment
Prior art date
Application number
MXPA05008137A
Other languages
English (en)
Inventor
Karen J Coffman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA05008137A publication Critical patent/MXPA05008137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de formula I, (ver formula (I)), y las sales farmaceuticamente aceptables de los mismos; estos compuestos son utiles como agentes psicoterapeuticos.
MXPA05008137A 2003-01-31 2004-01-20 Antagonistas y agonistas de 5ht7. MXPA05008137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44436203P 2003-01-31 2003-01-31
PCT/IB2004/000172 WO2004067703A2 (en) 2003-01-31 2004-01-20 5ht7 antagonists and inverse agonists

Publications (1)

Publication Number Publication Date
MXPA05008137A true MXPA05008137A (es) 2005-09-30

Family

ID=32825411

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008137A MXPA05008137A (es) 2003-01-31 2004-01-20 Antagonistas y agonistas de 5ht7.

Country Status (7)

Country Link
US (1) US20040229874A1 (es)
EP (1) EP1592772A2 (es)
JP (1) JP2006516604A (es)
BR (1) BRPI0406704A (es)
CA (1) CA2514656A1 (es)
MX (1) MXPA05008137A (es)
WO (1) WO2004067703A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801812A1 (ru) * 2003-09-17 2009-06-30 Янссен Фармацевтика Н.В. Сопряженные гетероциклические соединения
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound
EA016529B1 (ru) 2007-05-11 2012-05-30 Эли Лилли Энд Компани 2-[4-(пиразол-4-илалкил)пиперазин-1-ил]-3-фенилпиразины и -пиридины и 3-[4-(пиразол-4-илалкил)пиперазин-1-ил]-2-фенилпиридины в качестве антагонистов рецепторов 5-ht
TW200914020A (en) 2007-08-28 2009-04-01 Lilly Co Eli Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists
DK2201002T3 (da) * 2007-10-12 2012-04-10 Lilly Co Eli 5-HT7-receptorantagonister
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3738955A1 (en) 2013-03-11 2020-11-18 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
CN105906614A (zh) * 2016-05-12 2016-08-31 山东罗欣药业集团股份有限公司 一种奥美沙坦酯的制备方法
IL291029B2 (en) 2016-11-15 2024-06-01 Univ Temple New modulators of 5-hydroxytryptamine receptor 7 and a method of using them
JP7365238B2 (ja) 2017-03-21 2023-10-19 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション ５－ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147200A (en) * 1874-02-03 Improvement in spinning-wheels
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US6159979A (en) * 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
DE60011269T2 (de) * 1999-08-12 2005-06-23 Nps Allelix Corp., Mississauga Azaidole mit serotonin rezeptor affinität
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use

Also Published As

Publication number Publication date
BRPI0406704A (pt) 2005-12-20
WO2004067703A2 (en) 2004-08-12
WO2004067703A3 (en) 2004-11-04
US20040229874A1 (en) 2004-11-18
EP1592772A2 (en) 2005-11-09
CA2514656A1 (en) 2004-08-12
JP2006516604A (ja) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2004063864A3 (en) Method and system for computerized sexual function assessment of female users
Sanson-Fisher et al. Adaptation and validation of the SF-36 Health Survey for use in Australia
Amorim et al. Virtual reality therapy for rehabilitation of balance in the elderly: a systematic review and META-analysis
Sutton et al. Eliciting salient beliefs in research on the theory of planned behaviour: The effect of question wording
Hanin et al. Performance affect in junior ice hockey players: An application of the individual zones of optimal functioning model
Corbetta et al. Rehabilitation that incorporates virtual reality is more effective than standard rehabilitation for improving walking speed, balance and mobility after stroke: a systematic review
Lenker et al. A review of conceptual models for assistive technology outcomes research and practice
Mayer et al. Changes in health behaviors of older adults: the San Diego Medicare Preventive Health Project
MXPA05008137A (es) Antagonistas y agonistas de 5ht7.
Lin et al. Assessing the stroke-specific quality of life for outcome measurement in stroke rehabilitation: minimal detectable change and clinically important difference
Lenert et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores
Choi et al. The efficacy of female condom skills training in HIV risk reduction among women: a randomized controlled trial
Thomas et al. Disordered eating and injuries among adolescent ballet dancers
Dennerstein et al. Evaluation of a short scale to assess female sexual functioning
Palmcrantz et al. An interactive distance solution for stroke rehabilitation in the home setting–A feasibility study
Abudarham et al. Same critical features are used for identification of familiarized and unfamiliar faces
Learman et al. No differences in outcomes in people with low back pain who met the clinical prediction rule for lumbar spine manipulation when a pragmatic non-thrust manipulation was used as the comparator
Versluys et al. The influence of leg-to-body ratio, arm-to-body ratio and intra-limb ratio on male human attractiveness
Corcoran Interpersonal stress and burnout: Unraveling the role of empathy
Wright et al. Metronome‐Cued Stepping in Place after Hemiparetic Stroke: Comparison of a One‐and Two‐Tone Beat
Chan et al. Judo‐based exercise programs to improve health outcomes in middle‐aged and older adults with no judo experience: A scoping review
Rosenblum et al. Reliability and concurrent validity of the narrow path walking test in persons with multiple sclerosis
Veisani et al. Health related quality of life in the female-headed households
Nyarko et al. Prevalence and predictors of hypertension history among Ghanaian men
Montilla et al. Effectiveness of virtual reality in balance training for fall prevention in older adults: systematic review

Legal Events

Date Code Title Description
FA Abandonment or withdrawal